Ayala's Stock Surges After Ladenburg Initiates Coverage With Price Target Of $29

by Vandana Singh, Benzinga Editor

July 13, 2021 10:15 AM | 1 min read |

Ayala Pharmaceuticals Inc AYLA initiated with Buy with a $29 (around 120% upside) at Ladenburg Thalmann analyst price target.
The analyst says the company has the most diversified gamma-secretase inhibitor play in the public markets.
Demir sees near-to-medium term value play considering Ayala's "wide clinical pipeline that offers plenty of interesting /compelling optionality."
In April, the first patient was dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for multiple myeloma.
Ayala expects an initial interim data read-out from part A of desmoid tumor Phase 2/3 pivotal trial study and dose selection by mid-2022.
Cash and cash equivalents of $56 million are sufficient to provide a cash runway into 2023.
Price Action: AYLA shares are up 17.3% at $12.43 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Price Target Initiation Analyst Ratings General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.